Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET

Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) –

Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with

Company to Host Conference Call with Live Q&A, February 26, 2025, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 12,

            MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 (GlobeNewswire) –

MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a

Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of

MDxHealth to Present Third Quarter 2024 Financial Resultsand Corporate Update on November 6 Company to Host Conference Call with Live Q&A, November 6, 2024, at

MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the

MDxHealth Announces Launch of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company”),

MDxHealth Reports Q2 and Half Year 2024 Results Year-over-year Q2 revenues increase by 32% to $22.2 millionYear-over-year H1 revenues increase by 34% to 42.0 millionConference

MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A,

            MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenuesand Raises 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire)

            Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA

NEWS RELEASE25 OCTOBER 2023, 4PM ET / 22:00 CET MDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8 Company to

NEWS RELEASE September 26, 2023, 5:00PM EDT / 23:00 CET             Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of

        Mdxhealth to Present at Upcoming Investor Conferences IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 (GlobeNewswire) – Mdxhealth SA (Nasdaq:

MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 millionIncreasing 2024 revenue guidance to $83-85 million,

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42%2023 gross margin expanded